EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis

Wenqi Tian, Shanshan Peng, Fanfan Xu, Xiaotong Kong, Ying Li, Wei Zhang, Zhaojun Liu, Huixue Zhang, Jianjian Wang, Lihua Wang

Frontiers in Cellular and Infection Microbiology · 10.04.2026 · 16

DOI: 10.3389/fcimb.2026.1726788 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 10.04.2026. Verfasst von Wenqi Tian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Autoimmune, Experimental, Dysbiosis, Gastrointestinal Microbiome, Homeostasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Myasthenia Gravis (MG) is an acquired autoimmune disease. The imbalance between Th17 and Treg cells plays a crucial role in the pathogenesis of MG. A stable intestinal microbiota is essential for maintaining immune balance, a function primarily mediated by the Th17/Treg axis. This study aims to explore the role of gut microbiota in the pathogenesis of experimental autoimmune myasthenia gravis (EAMG) to identify potential new treatment strategies.

Methods

An EAMG model was established in Lewis rats by immunization with the AChRα97-116 peptide segment. The composition and structure of the gut microbiota were analyzed by 16S rRNA sequencing. The serum levels of inflammatory cytokines (IFN-γ, TNF-α, IL-17, IL-10), AChR-Ab, and LPS were measured using the ELISA method. Colon tissues were subjected to Hematoxylin and eosin (H&E) staining, and Claudin-1 and Muc2 expression was analyzed via immunofluorescence. A microbiota disorder animal model was established by administering an antibiotic mixture via gavage, followed by fecal microbiota transplantation. Splenic CD3+CD4+IL-17A+ Th17 cells and CD3+CD4+CD25+Foxp3+ Treg cells were quantified by flow cytometry.

Results

1. Compositional and structural changes of the gut microbiota in EAMG. Compared with HC, the serum levels of IFN-γ, TNF-α, IL-17, and AChR-Ab in EAMG were significantly increased (P < 0.0001), while the serum level of IL-10 was significantly decreased (P < 0.0001), and the serum level of LPS was increased (P < 0.01). The protein levels of Claudin-1 (P < 0.001) and Muc2 (P < 0.05) in the colon were significantly reduced in EAMG. 2. Relative to rats receiving HC microbiota transplantation (HMb), those receiving EAMG microbiota transplantation (MMb) exhibited significantly elevated serum levels of AChR-Ab (P < 0.01), TNF-α (P < 0.05), IL-17 (P < 0.05), and LPS (P < 0.01), alongside significantly reduced colonic levels of Claudin-1 (P < 0.05) and Muc2 (P < 0.0001). 3. Compared with the EAMG group, the ABX + EAMG group (EAMG with microbiota dysbiosis) exhibited significantly lower colonic levels of Claudin-1 and Muc2 (P < 0.05), a significantly greater splenic Th17/Treg cell imbalance (P < 0.01), and significantly higher serum AChR-Ab levels (P < 0.01).

Discussion

The gut microbiota is intricately linked to the progression of EAMG. Microbiota dysbiosis can exacerbate intestinal barrier damage in EAMG and may further influence the pathological changes of myasthenia by disrupting the Th17/Treg immune balance. These findings suggest a novel therapeutic strategy for the treatment of myasthenia gravis by re-establishing microbial homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia Gravis, Autoimmune, ExperimentalDysbiosisGastrointestinal MicrobiomeHomeostasisAnimalsRats, Inbred LewTh17 CellsT-Lymphocytes, RegulatoryCytokinesRatsIntestinal Barrier FunctionDisease Models, AnimalFemaleRNA, Ribosomal, 16SIntestinal MucosaFecal Microbiota TransplantationColon

Stichwörter der Autor:innen

Th17/Treg cellexperimental autoimmune myasthenia gravis(EAMG)fecal microbiota transplantation (FMT)gut microbiotaintestinal barrier

Substanzen

CytokinesRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Zitieren

APA

Tian, W., Peng, S., Xu, F., Kong, X., Li, Y., Zhang, W., Liu, Z., Zhang, H., Wang, J., & Wang, L. (2026). Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1726788

Vancouver

Tian W, Peng S, Xu F, Kong X, Li Y, Zhang W, et al. Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1726788

BibTeX
@article{Tian2026,
  author = {Tian, Wenqi and Peng, Shanshan and Xu, Fanfan and Kong, Xiaotong and Li, Ying and Zhang, Wei and Liu, Zhaojun and Zhang, Huixue and Wang, Jianjian and Wang, Lihua},
  title = {Disruption of intestinal barrier and immune homeostasis links gut microbiota dysbiosis to aggravated experimental autoimmune myasthenia gravis},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1726788}
}
Kostenlos starten →